Mode
Text Size
Log in / Sign up

dacarbazine

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dacarbazine

42 trials tracked of dacarbazine: 14 in phase 3 or 4 and 5 with published results. The most-cited published study has 2662 citations.

42Trials tracked
14Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 3 14 Phase 2 27 Phase 1 1
  1. Phase 3 A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) Completed · 2,662 cited
  2. Phase 3 Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Completed · 491 cited
  3. Phase 3 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma Completed · 322 cited
  4. Phase 3 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed · 273 cited
  5. Phase 3 Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma Completed · 25 cited
  6. Phase 3 A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine Completed
Show 36 more trials
  1. Phase 3 Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) Completed
  2. Phase 3 A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma Completed
  3. Phase 3 S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma Completed
  4. Phase 3 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Completed
  5. Phase 3 A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) Completed
  6. Phase 3 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Completed
  7. Phase 3 Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma Completed
  8. Phase 3 Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma Completed
  9. Phase 2 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Completed
  10. Phase 2 Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma Completed
  11. Phase 2 Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Completed
  12. Phase 2 Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma Completed
  13. Phase 2 Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance Completed
  14. Phase 2 A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma Completed
  15. Phase 2 Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) Completed
  16. Phase 2 A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma Completed
  17. Phase 2 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma Completed
  18. Phase 2 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma Completed
  19. Phase 2 E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma Completed
  20. Phase 2 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) Completed
  21. Phase 2 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed
  22. Phase 2 Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) Completed
  23. Phase 2 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Completed
  24. Phase 2 Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients Completed
  25. Phase 2 Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease Completed
  26. Phase 2 A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma Completed
  27. Phase 2 Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma Completed
  28. Phase 2 Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma Completed
  29. Phase 2 Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma Completed
  30. Phase 2 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma Completed
  31. Phase 2 Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Completed
  32. Phase 2 Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma Completed
  33. Phase 2 Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Completed
  34. Phase 2 Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma Completed
  35. Phase 2 Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Completed
  36. Phase 1 Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine Completed

Showing the 42 most-cited and recently-updated of 42 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.